Andera Partners, a European private equity player, is leading a $48.5 million Series A financing round for medical device company BioVentrix. BioVentrix is developing minimally invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodelling process in patients with congestive heart failure.
Billion Photos Shutterstock
726217735
Finance concept.
The investor syndicate also includes Cormorant Asset Management, Taglich Brothers, Squarepoint Capital, and Richmond Brothers. In conjunction with the financing, BioVentrix appointed Raphael Wisniewski of Andera Partners and Bihua Chen of Cormorant Asset Management to its Board of Directors.
The financing will support the completion of BioVentrix’ Premarket Approval (PMA) submission for its Revivent TC System, fund expanded access to allow additional procedures following the successful completion of enrolment in its PMA study and initial preparations for commercial launch. BioVentrix recently received approval from the U.S. Food and Drug Administration for an Expanded Access Program following the successful completion of enrolment in ALIVE, a prospective, multi-centre, dual-arm pivotal study.
The BioVentrix Revivent TC System is designed to support a minimally invasive procedure to treat a dilated left ventricle of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and extensive left ventricular scar who have a suboptimal response to guideline-directed medical therapy. The Revivent TC procedure employs myocardial micro-anchor implants to reconstruct the dilated left ventricle resulting in a more efficient chamber.
Jim Dillon, president & CEO of BioVentrix, said: “Our ability to complete a financing with prominent world class investors and the support of our existing shareholders is a testament to our team and the size of the untapped market opportunity in front of us. Treating advanced heart failure patients through left ventricular restoration is now recognised by the clinical cardiology community as an approach whose time has come.”
Raphaël Wisniewski, partner at Andera Partners, added: “We are excited to lead this significant financing round and to support the talented management at BioVentrix as they work to bring a new therapeutic solution to patients with advanced ischemic heart failure.”
